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ABSTRACT 
Introduction:  
Membranous nephropathy is an autoimmune disease that targets glomeruli of the kidney. 
Previous discoveries in membranous nephropathy include the discovery of megalin as an 
antigen in the proximal tubular brush border fraction (Fx1A) and glomeruli of Heymann 
nephritis rats, identification of neutral endopeptidase in alloimmune neonatal 
nephropathy, and discovery of PLA2R and THSD7A as causal antigens in approximately 
80-85% of primary membranous nephropathy cases. It was then recognized that there 
must be other antigens responsible for the remaining 15-20% of cases.  
Objectives:  
The current study aims to screen membranous nephropathy patient serum samples via 
Western blotting for reactivity with potential antigens in protein extracts of normal 
human glomeruli, purify potential membranous nephropathy antigens, identify them with 
mass spectrometry, and validate these identifications with immunoprecipitation and 
immunohistochemical analysis. Previously, work had been done to identify one novel, 58 
kDa antigen. A second novel antigen had been shown in the proximal tubule brush 
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border. Finally, a third protein, CR1, was shown to contain corresponding antibodies in 
the antibody preparation used in the rat model of membranous nephropathy, making the 
antigen a protein of interest in human primary membranous nephropathy.  
Methods:  
Using human glomeruli obtained by detergent extraction, we isolated extracellular 
domains and identified two novel antigens, called 58-kDa and brush-border, with patient 
serum. We attempted to further purify the 58-kDa antigen with lectin binding columns 
and partition phase separation. Upon the identification of a small cohort of cases 
associated with autoimmune tubulointerstitial nephritis, we set out to determine if these 
sera recognized a novel antigen. Prior to screening human glomerular extract with these 
sera, we exposed it to partial proteolysis with trypsin, reducing agent β-mercaptoethanol, 
and tubular elements to further characterize the antigen before it was pulled down with 
anti-brush-border antigen+ and control IgG4 and analyzed by mass spectrometry. The 
third and final antigen we investigated was CR1, which we screened with membranous 
nephropathy sera and immunoblotted its antibody against different protein preparations.  
Results:  
Labeling of the extracellular portions of the 58-kDa and brush-border antigens with biotin 
was successful. It was determined that the 58-kDa antigen was not glycosylated due to its 
inability to bind lectin columns. The 58-kDa antigen was present in the hydrophilic layer 
when separated with tritonX-114 detergent. Partial proteolysis of the brush-border 
antigen with trypsin yielded bands at 140 kDa, 120 kDa and 95 kDa. The brush-border 
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antigen was destroyed under reducing conditions. Candidate proteins for the brush-border 
antigen as determined by mass spectrometry include megalin and SVEP1. Membranous 
nephropathy sera were shown to be negative for anti-CR1+ antibody, and anti-CR1+ 
antibody was reactive with glomeruli and the TBS supernatant fraction. 
Conclusions:  
This study suggests that the 58-kDa antigen which has antibodies in some human primary 
membranous nephropathy sera contains extracellular portion(s), is not glycosylated, but is 
membrane-associated. The data indicate that there is also potential for a membranous 
nephropathy antigen in the tubular brush border with an immunoreactive element around 
95 kDa in size, that is sensitive to reducing conditions. Preliminary mass spectrometry 
information points toward megalin as the identification of this antigen. CR1 does not 
appear to be a causal antigen in human primary membranous nephropathy. 
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INTRODUCTION 
Nephrotic Syndrome from Membranous Nephropathy 
Membranous nephropathy (MN) is an organ specific autoimmune disease of the 
kidney that targets the specialized blood vessels of the glomerulus that comprise the 
glomerular filtration barrier. MN is the major cause of nephrotic syndrome of non-
diabetic origin in adults (Ronco & Debiec, 2015). Nephrotic syndrome, which can be 
caused by a number of etiologies that all affect the podocyte and/or glomerular filtration 
barrier, presents as proteinuria, hypoalbuminemia, hyperlipidemia, and generalized 
edema (Kemp, Burns, & Brown, 2008). The typical fates of this condition in MN seen 
clinically are spontaneous remission, or continued proteinuria resulting in either stable 
renal function or end-stage renal failure (Ronco & Debiec, 2015). Spontaneous remission 
of MN is seen in 40% of cases, the chances of which are increased by baseline 
proteinuria of less than 8 g per day, female sex, less than 50 years of age, and preserved 
renal function at presentation. Nephrotic syndrome is triggered by a fall in osmotic 
pressure due to loss of protein in the urine, which favors fluid movement out of the 
intravascular space and into the interstitium or other spaces. This fluid movement, in 
addition to direct stimulation of sodium absorption due to the effects of filtered proteins, 
leads the kidneys to progressively retain sodium, followed by water, until a new 
equilibrium is established between the vascular and interstitial spaces (Perlman, Heung, 
& Ix, 2013). Hypoalbuminemia also leads to an increase in apolipoprotein from the liver 
(Kemp et al., 2008).  
2 
Nephrotic syndrome in membranous nephropathy is caused by immune-mediated 
damage to glomeruli at the slit diaphragm of podocyte foot processes which activates the 
complement system, usually via the classical pathway (Beck, 2014). The damaged foot 
processes secondarily secrete matrix material and allow calcium influx that cause a less 
differentiated podocyte phenotype including loss of foot processes and slit-diaphragm 
structures and expansion of the glomerular basement membrane (GBM, figure 1A), the 
specialized extracellular matrix between podocytes and the endothelial cells of the 
glomerulus (Cybulsky, 2011; figure 1), which may still be present after remission due to 
slow restoration of the GBM (Beck, 2014). The maintenance of the slit diaphragm in 
healthy individuals is critical to regulating what the GBM is permeable to according to 
size and charge (Krtil, Pláteník, Kazderová, Tesař, & Zima, 2007). 
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Figure 1. The kidney. A. Glomerulus and capillary. B. Glomerulus and glomerular 
filtration barrier (podocytes, glomerular basement membrane, and epithelial cells). (After 
McGraw Hill Education, 2015). 
 
The Course of Membranous Nephropathy 
MN is a pattern characterized in light microscopy by more thickness to the 
capillary wall compared to normal (Jones, 1957); in electron microscopy by immune 
deposits of more electron density below the epithelium (Movat & McGreggor, 1959); 
and, in immunofluorescence by peripheral capillary loop staining for IgG that is fine and 
granular (Mellors & Ortega, 1956). There are two forms of MN: primary and secondary. 
Primary (previously known as “idiopathic”) MN describes the 75% of MN cases that 
show subepithelial IgG deposits by immunofluorescence microscopy (mostly IgG4 with 
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variable amounts of IgG1) and subepithelial and intramembranous electron dense 
deposits by electron microscopy in the absence of any other known association 
(Cybulsky, 2011). Primary MN is more common in men than in women; in fact, when 
observed in women it can indicate an underlying cause of lupus.  
When the other 25% of MN cases are caused by other systemic autoimmune 
processes like diseases, medications, or exposures in this way, they are classified as 
secondary MN (Ma, Sandor, & Beck, 2013). Secondary MN can be identified by 
secondary causes and histopathological features, frequently with atypical lesions (Ma et 
al., 2013). Subepithelial and mesangial extraglomerular IgG1 and IgG2 deposits are seen 
by immunofluorescence microscopy and electron microscopy, which also shows 
intramembranous electron dense deposits and, in the case of lupus, tubuloreticular 
inclusions (Cybulsky, 2011). Subendothelial and mesangial deposits are often found in 
lupus-associated MN in addition to subepithelial and paramesangial deposits. In both 
types of MN, staging of the disease is done according to the extent to which subepithelial 
immune deposits are surrounded by GBM.  
Causal Antigens in Membranous Nephropathy 
Experimental studies into the pathophysiology of MN date back to the Heymann 
nephritis model initially developed in 1959 (Heymann, Hackel, Harwood, Wilson, & 
Hunter, 1959). The model involved immunizing Lewis rats intraperitoneally using 
homologous renal homogenate and complete Freund’s adjuvant to induce nephropathy 
identical to human MN clinically and histopathologically, complete with presence of 
subepithelial immune deposits via light, immunofluorescence, and electron microscopy. 
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Over time, antigenic activity in this model was narrowed down to a tubule rich (brush-
border) fraction called Fx1A that was thought to form immune complexes in the blood. A 
seminal study performed at Boston University in 1979, however, revealed that the anti-
Fx1A antibodies instead bound in situ to a fixed antigen present within the glomerular 
filtration barrier. Years later this fixed antigen was identified on podocytes as megalin 
and its chaperone, receptor-associated protein (Kerjaschki & Farquhar, 1982). However, 
once it was discovered that megalin was not present on human podocytes (Lundgren et 
al., 1997), and thus could not cause human primary MN, the search for a causal antigen in 
humans was back on.  
Fortunately, in 2002, neutral endopeptidase (NEP) was discovered by Ronco, 
Debiec, and colleges as the antigenic target of circulating antibodies in alloimmune 
neonatal nephropathy. While this antigen was only causal in this rare disease, it did 
inspire researchers to continue the search for antigens responsible for MN. Then in 2009, 
Beck et al. discovered M-type phospholipase A2 receptor-1 (PLA2R) as the antigenic 
target in autoimmune adult MN (Figure 2A).  
 
α-PLA2R+ serum 
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Figure 2. Phospholipase A2 Receptor. A shows the comparable results of Western blot 
with guinea pig anti-PLA2R and membranous nephropathy serum against human 
glomerular extract and recombinant PLA2R. Each sample is shown deglycosylated (+ 
PNGase F) and in its natural state (- PNGaseF), illustrating a difference in size between 
the two conditions. B illustrates the structure of PLA2R, including the N-terminal 
cysteine-rich region (CysR), a fibronectin type II domain (FNII), eight C-type lectin-like 
domains (CTLD), a transmembrane domain (TM), and an intracellular C-terminal tail 
(After Beck et al. 2009).  
 
PLA2R is a type 1 transmembrane receptor that constitutes one of four members 
of the mannose-receptor family in mammals (Figure 2B). It demonstrates a conserved 
domain structure and undergoes endocytic recycling so that there is a constant source of it 
at the podocyte membrane for immune complex formation (Beck et al., 2009). In 2009, 
Beck et al. found that when incubated with reactive serum samples from MN patients, 
human glomerular extract (HGE) yield the same 185-kiloDalton (kDa) band via gel 
electrophoresis that is also detected by guinea pig polyclonal anti-PLA2R positive (α-
PLA2R+) serum via Western blot. Also, immune-precipitates from HGE with human MN 
B. 
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sera could be Western blotted with the polyclonal anti-PLA2R antibody, showing that the 
autoantibodies in the sera identified the same protein as monospecific anti-PLA2R 
antiserum. This established the target antigen as PLA2R.  
It has been shown that about 70% of primary MN patients have antibodies to the 
antigen PLA2R, (Beck et al., 2009). Beck et al. discovered that anti-PLA2R antibodies are 
most often of the IgG4 subclass. In fact, PLA2R co-localizes with IgG4 in the fine, 
granular pattern that is typical of MN (Beck et al., 2009). However, IgG4 does not 
activate the classical pathway of complement although there is emerging evidence that it 
may activate the lectin pathway. The discovery of PLA2R allowed for retrospective 
diagnosis of PLA2R-related MN in archival kidney biopsies (Ronco & Debiec, 2015). 
Some studies show that the concentration of α-PLA2R+ serum correlates with urinary 
protein output and disease activity. Therefore, a high titer signifies a decreased possibility 
of spontaneous or immunosuppressant-induced remission, increased risk of nephrotic 
syndrome in non-nephrotic patients, deterioration in renal function, and an increased time 
interval between the start of immunosuppressive treatment and remission (Ronco & 
Debiec, 2015). 
There are other antigens responsible in the remaining cases, such as the recently 
discovered thrombospondin type-1 domain-containing 7A, a 250 kDa, type-1 
transmembrane protein identified by Tomas et al. in 2014 via mass spectrometry. 
Thrombospondin type-1 domain-containing 7A (THSD7A) shares several features with 
PLA2R, including N-glycosylation, membranous location, reactivity with serum only 
under non-reducing conditions, and the predominant IgG subclass of autoantibodies to it 
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being IgG4 (Tomas et al., 2014). THSD7A consists of a large extracellular region of 
eleven thrombospondin type-1 repeats and one arginine-glycine-aspartic acid (RGD) 
motif; a single transmembrane domain; and, a short intracellular tail (Figure 3). 
Autoantibodies to THSD7A recognize one or more conformation-dependent epitopes in 
native and recombinant THSD7A in 5-10% of primary MN patients negative for α-
PLA2R. Furthermore, it was found to be located on or close to the podocyte foot 
processes, not the glomerular basement membrane (Tomas et al., 2014).  
 
Figure 3. Thrombospondin type-1 domain-containing 7A. Pictured are: the 
thrombospondin domain (TSD) repeats and arginine-glycine-aspartic acid (RGD) motif 
of the extracellular domain; the transmembrane (TM) region; and, the short intracellular 
tail (as well as a signal peptide, in blue; after Tomas et al., 2014).  
 
Characterizing Three Novel Antigens Associated with Autoimmune Kidney Disease 
As PLA2R and THSD7A do not account for all cases of primary MN, the search 
continues for minor antigens in this disease. Iwakura et al. showed that 38% of all 
primary MN biopsies were negative for both PLA2R and THSD7A. Hence, it is very 
likely that there are antigens yet to be identified (Iwakura, Ohashi, Kato, Baba, & 
Yasuda, 2015). However, these antigens have yet to be found using existing techniques. 
This could be due to the very small numbers of patients reactive with the other antigens. 
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It could also be that these minor proteins are not extractable using detergent, i.e. they are 
possibly components of the GBM. Furthermore, these marginal antigens may react with 
non-IgG4 autoantibodies, and thus are not detected on Western blot by anti-IgG4 
secondary antibody, which is the predominant immunoglobulin subclass in glomerular 
deposits. Finally, it could be that the conformation of the epitope of these proteins is 
destroyed by the Western blot procedure. Overcoming these hurdles will be key in 
classifying the unidentified antigens responsible in the remaining 15-20% of primary MN 
cases.  
One such potential antigen (so-called “58 kDa-antigen”) was originally identified 
by the serum of patient MN 07-15 which was shown to positively bind to an antigen in 
the 58-kDa region on Western blot. The gel region corresponding to the Western blot 
signal at 58 kDa was excised and analyzed by mass spectrometry after 
immunoprecipitation with patient serum. Previous work in the lab (Beck, unpublished 
data) that was done with our mass spectrometry collaborators at the University of 
Louisville, analyzed the excised band. Biochemical features of these proteins were 
compared to the characteristics of the novel 58 kDa-antigen (Table 1). While some of the 
proteins share characteristics with the novel antigen, we decided to search for proteins 
with extracellular components that were more likely to be targeted by autoantibodies. The 
58-kDa antigen has been identified as a membrane-associated protein by making 
“membrane preps” via cell lysis and high-speed ultracentrifugation of the cellular 
membranes (Eric Eisenberg, unpublished data). This protein remains unidentified, but we 
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have sporadically found reactivity for this antigen in other patients with primary MN. 
Thus we repeated efforts to try to identify this antigen.  
Table 1. List of best candidate proteins for 58-kDa antigen from mass spectrometry 
analyses. Characteristics that fit the protein of interest are marked in red. (Data from 
“Human Protein Reference Database,” n.d.) 
 
Protein Size Glycosylation Tissue Expression Cellular 
Location 
Annexin A11 54 No White blood cells, 
ovary, semen 
Cytoplasm and 
nucleus 
ATP synthase, 
alpha 
60 No Heart, pancreas, white 
blood cells, ovary, 
plasma, saliva, serum 
Mitochondrion, 
extracellular, 
zymogen granule 
ATP synthase, 
beta 
57 No Heart, pancreas, 
kidney, liver, ovary, 
muscle, urine 
Mitochondrion, 
plasma 
membrane, 
nucleolus, 
extracellular 
Complement 
component C1q, B 
chain 
27 No Brain, nervous system, 
plasma, spinal cord, 
umbilical vein 
endothelial cell 
Extracellular 
Hydroxysteroid 
(17-beta) 
dehydrogenase 4 
80 No Liver, heart, prostate, 
testes 
Peroxisome, 
cytoplasm, 
nucleosome, 
mitochondrion 
PDIA3 57 N Liver, colon, kidney, 
testis, lymph node, 
cerebral cortex, 
pancreas  
Endoplasmic 
reticulum 
Prenylcystein 
oxidase 1 
57 No Brain, colon, heart, 
kidney, liver, lung, 
ovary, pancreas, 
muscle, spleen, testis, 
urine 
Lysosome 
Properdin 51 No White blood cells, 
plasma, endothelial 
cells,  
Extracellular 
Vimentin 54 O Lacrimal gland, white 
blood cells, muscle, 
ovary, plasma, saliva, 
urine 
Intermediate 
filament, ECM 
fraction, Golgi 
apparatus, ER 
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Complement receptor 1 (CR1) is another potential antigen of interest in 
membranous nephropathy in that in the Heymann nephritis model, antibodies that 
neutralized the effect of complement receptor 1-related protein y (Crry), a rodent 
complement regulatory protein related to CR1, were found in the sheep anti-Fx1A 
preparation that were necessary for causing disease. Complement receptors modulate the 
effects of the complement system by binding complement proteins (Lee, 2012). CR1 is 
involved in phagocytosis, clearance of immune complexes, and downregulation of 
complement. It also regulates complement pathways in human cells to protect them from 
damage. The only epithelial site of expression of CR1 in the kidney is at the podocyte, 
where it has been shown to act as a potent regulator of the alternative pathway, in 
addition to the classical pathway (Java, Liszewski, Hourcade, Zhang, & Atkinson, 2015). 
The regulatory activity of CR1 is mediated by decay accelerating factor, and only works 
intrinsically (only on the cell on which it was expressed). The cleavage of these 
complement factors also occurs with Factor I as a cofactor. It regulates the alternative 
pathway via a rapid initial response with decay accelerating activity, followed by 
degradation via cofactor activity.  
Yet another autoantigen of interest was identified in a recent publication. The 
authors noted the existence of a potentially novel antigen associated with minor 
glomerular subepithelial deposits as in MN but whose major site of immune complex 
formation appears to be at the base of the proximal tubule, leading to an immune-
mediated tubulointerstitial nephritis that caused end-stage kidney disease (Rosales et al., 
2015). This condition is characterized by tubular injury and interstitial inflammation on 
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light microscopy; granular tubular basement membrane staining for IgG, C4d, and C3 on 
immunofluorescence; and electron-dense tubular basement membrane deposits staining 
for IgG1, but no endocapillary hypercellularity or GBM abnormality nor staining for 
PLA2R. Small, sparse subepithelial deposits are also observed in the glomeruli. The fact 
that the disease rapidly occurred after kidney transplantation, and that serum from the 
patient - both pre- and post-transplantation - reacted with normal human brush border on 
indirect immunofluorescence provide evidence for circulating autoantibodies to a brush 
border protein. Sera from similar cases have been made available to us, and preliminary 
data from another member of the laboratory (figure 4; unpublished data) has shown that it 
also is reactive with brush border proteins in normal neonatal rat kidney. What exactly 
this antigen is has yet to be determined, but megalin, CD10, and maltase (three known 
brush border proteins) have been ruled out based on immunofluorescence data (Rosales et 
al., 2015).  
 
Figure 4. Examples of positive & negative staining for the brush border antigen 
(200x). Negative staining of newborn rat glomeruli for the brush border antigen with 
normal human serum (1:100) (left) and positive staining with patient serum (1:100) 
(right) are shown. Exposure time was 90 milliseconds. From Youngsoo Song, 
unpublished data.  
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OBJECTIVES 
 Methods developed in our laboratory have thus far utilized patient-derived 
autoantibodies to identify two important antigens in membranous nephropathy. Antigens 
targeted by patient antibodies in MN are starting to be discovered with the established 
protocols in place. However, the existing antigens only explain, at best, 80-85% of cases 
of MN and there remains a significant proportion of cases in which we do not have useful 
biomarkers of disease activity. There are still other antigens that could be targeted. The 
aim of this study is to shed light on the process of characterizing these antigens by 
applying the current discovery process to two such potential antigens. The specific 
objectives of the study are: to screen serum samples via Western blotting; to purify 
potential MN antigens; to identify them with mass spectrometry; and to validate their 
identity with immunoprecipitation and immunohistochemical analysis.  
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METHODS 
Preparation of Human Glomerular and Tubular Extracts 
Glomeruli and tubules were obtained by sieving (Fisher Scientific Nos. 140, 80, 
and 200) cortical portions of human kidneys that had been deemed unsuitable for 
transplantation from the New England Organ Bank with cold phosphate buffered saline 
(PBS). Glomeruli and a small proportion of intact tubular segments were retained on the 
final #200 sieve and were collected as the glomerular fraction (figure 9). Tubular and 
interstitial cortical elements that passed through the #200 sieve were also collected for 
use in later experiments. Proteins were extracted with radioimmunoprecipitation-assay 
buffer (RIPA; Boston BioProducts), and contaminating IgG was removed via incubation 
with Immobilized Protein G Plus (Fisher Scientific). The resulting preparations are 
termed human glomerular extract (HGE) or human tubular cell extract (HTE).  A 
glomerular tris buffered saline (TBS) supernatant fraction was also prepared in which 
glomeruli were incubated at 37°C for 1 hour in TBS and the resultant supernatant, after 
centrifugation for 10 minutes at 14,000 rotations per minute (rpm), was collected. This 
fraction is known to contain a subcellular “shed” membrane fraction and contains both 
PLA2R and THSD7A.  
Western Blot 
 Western blotting was done on 4-15% Mini-PROTEAN TGX gels from Biorad 
with 25 microliters (μL) of sample loaded per lane (or 10 μL of Invitrogen See Blue Plus 
2 Prestained Standard). Gels were run in 1x running buffer (Boston BioProducts). 1x 
non-reducing gel loading buffer (Boston BioProducts) was added to sample, and then 
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boiled at 95°C for five minutes, before being loaded into the gel. We also added beta-
mercaptoethanol to a final concentration of 2% prior to boiling when experiments called 
for reducing conditions. Gels were run and then transferred onto nitrocellulose 
membranes. Blots were then blocked in 10% milk/TBS-tween (TBST) for one to four 
hours at room temperature and incubated in patient serum diluted in 10% milk/TBST at 
4°C overnight. 
The next day, blots were incubated for one hour at room temperature in sheep 
anti-human IgG4 at 1:3000 or sheep anti-human IgG1 at 1:4000 (both from The Binding 
Site) and donkey anti-sheep IgG at 1: 10,000 (Jackson ImmunoResearch) with washes in 
TBST in between incubations. Blots were quickly rinsed with distilled water and rocked 
at room temperature in enhanced chemiluminescence (ECL) solution (20 mL Tris, pH 
8.5; 100 μL luminol; 44 μL p-coumaric acid; and 5.5 μL hydrogen peroxide) for two or 
three minutes. Then the blots were routinely exposed for ten seconds, thirty seconds, and 
two minutes before being developed in a Kodak X-Omat developer.  
Biotinylation of 58-kDa Antigen 
EZ-Link™ Sulfo-NHS-Biotin (Thermo Scientific) was incubated for 30 minutes 
with isolated human glomeruli in PBS. Then the biotin was washed off three times with 
PBS. Next, 500 μL of 2x RIPA + protease inhibitor was added and the mixture was 
incubated on ice for 40 minutes with intermittent vortexing to extract the proteins. After 
centrifugation, the supernatant containing the extracted biotinylated cell-surface proteins 
was incubated with streptavidin beads. Then we used a streptavidin bead pull-down to 
enrich these biotinylated proteins. The streptavidin beads were washed twice with one 
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milliliter (mL) of PBS at 10,000 rpm, incubated for one hour at 4°C with intermittent 
inversion, and centrifuged to separate the beads from the product that was not pulled 
down. Beads were then boiled with loading buffer and loaded onto a gel for Western 
blotting as above. Original, pull-down, and after pull-down fractions were run on a gel 
for Western blotting. Samples were blotted against streptavidin-HRP (to confirm that the 
biotinylation worked) and anti-58-kDa positive (α-58-kDa+) serum. Streptavidin-HRP 
strongly reacted with biotinylated HGE pull-down only, and not HGE pull-down that was 
not biotinylated (data not shown). 
Biotinylation of Brush-border Antigen 
 EZ-Link™ Sulfo-NHS-Biotin (Thermo Scientific) was incubated for 1 hour with 
an isolated human tubular fraction obtained by sieving (Fisher Scientific Nos. 140, 80, 
and 200) kidneys from the New England Organ Bank with cold PBS. The biotinylated 
tubules were resuspended in TBS, spun down, and the supernatant was removed. 
Hypotonic tris plus protease inhibitors was added to the tubules and frozen at -80°C for 
one hour. After thawing, the mixture was Dounce homogenized and 100 µL were saved 
and spun down for several minutes. Next, 3 mL of 2x RIPA + protease inhibitors were 
added and the mixture was incubated on ice for 40 minutes with intermittent vortexing. 
The extraction was then spun down and saved for Western blot and immunoprecipitation.  
Lectin Binding Assay 
To determine if a lectin column could be used to purify the 58-kDa antigen, 
approximately 300 μL of HGE was added to 500 μL of immobilized Wheat Germ 
Agglutinin (WGA; Vector Laboratories) and rotated at 4°C for one hour. Then the HGE 
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and beads were spun down, 75 μL of the supernatant were saved for a gel, and the 
remaining supernatant was run over concanavalin A (ConA) beads (Vector Laboratories) 
as above. The starting HGE fraction, HGE after the WGA column, and HGE after the 
ConA column fractions were run on a gel for Western blot analysis and each incubated 
against α-PLA2R+, anti-THSD7A positive (α-THSD7A+), and α-58-kDa-antigen+ 
diluted serum samples. The HGE fractions obtained after the lectin assays represents non-
lectin bound protein, thus any lectin-bound protein was expected to be on the column. 
Ion Exchange Columns 
 Three different types of mini Vivapure Ion Exchange Columns (strong cation 
exchange, weak cation exchange, and weak anion exchange; Vivascience Sartorius 
Group) were used in an attempt to purify and characterize the 58-kDa antigen. First, 
columns were equilibrated with 400 μL of 25 mM tris/hydrogen chloride (HCl), pH 8.0 
(anion exchanger) or sodium acetate, pH 5.5 (cation exchanger). Columns were 
centrifuged for five minutes at 2000 g at 4°C. Next, columns were loaded twice with 300 
μL of HGE diluted 1:2 in the respective equilibration buffers above and centrifuged at 
2000 g for five minutes. Then, columns were washed twice with 400 μL of 25 mM 
Tris/HCl, pH 8.0 or sodium acetate, pH 5, as above at room temperature. Finally, the 
columns were eluted with 400 μL of 0.5 M sodium chloride in 25 mM Tris/HCl, pH 8.0 
(anion exchanger) or in 25 mM sodium acetate, pH 5.5 (cation exchanger) and 
centrifuged at 2000 g for five minutes. The flow through after sample loading and the 
final eluate were saved and run on a gel for Western blotting as above. Primary antibody 
to the 58-kDa antigen and THSD7A was from two different patient sera at concentrations 
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of 1:100 and 1:200, respectively. The blots were then detected for IgG1 and IgG4, 
respectively, as described above.  
Affinity Purification 
 Twenty-five µL of HGE were loaded to each of eight lanes of 4-15% Mini-
PROTEAN TGX gels from which a strip corresponding in size to the 58-kDa antigen was 
cut. Nitrocellulose membranes were incubated overnight at 4°C in α-58-kDa antigen+ 
serum. The following day, the membrane was washed three times for ten minutes in 
TBST, quickly rinsed twice with 150 nM NaCl, and eluted of antibody with 0.1 M 
glycine, pH 2.5, ten times in succession. The elution step was then repeated and the acid 
was neutralized with 1x TBS, pH 7.4, and 50 mM Tris, pH 8.0. Next, the same 
membranes were blocked in 10% milk/TBST for 15 minutes and then they were 
incubated in 1:50 dilutions of each of the two eluates for one hour at room temperature. 
Both blots were then incubated and developed according to the Western blot protocol 
above.  
In order to see if we had actually been successful in eluting IgG from the 
membrane, we repeated a Western blot with the two eluates overnight at 4°C. In addition, 
each of the eluates were run on a gel and Western blotted against IgG1, 1:4000 for one 
hour. Finally, the affinity purification protocol was repeated with minced nitrocellulose 
strips incubated with acid heated to 60°C. Part of the eluted antibody was then used for 
Western blot, as before, and any IgG of the other part was removed with protein G beads. 
We used the purified antibody for Western blotting.  
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Partition Phase Separation 
 We pre-condensed the detergent Tx-114 according to established protocols 
(Ausubel et al., 2000) and incubated it in the presence of protease inhibitors with either 
whole human glomeruli or glomerular TBS supernatant, in order to separate the starting 
glomerular materials into a detergent and aqueous phase. The established separation 
process involves incubation on ice for 30 minutes, centrifugation for 10 minutes at 4°C 
(supernatant removed and replaced by an equal volume of ice cold TBS), incubation at 
37°C until the contents turn cloudy, and centrifugation for eight minutes at room 
temperature. The supernatant is then removed and some was saved to run on a gel, while 
the rest was added to 1/5 volume of Tx-114 before repeating the process to generate a 
second aqueous layer. Any IgG in the aqueous layers was removed with protein G beads. 
Then we ran a Western blot with the original glomerular TBS supernatant fraction and 
the aqueous fractions against α-PLA2R+ and α-58-kDa antigen+ sera.  
Immunoprecipitation of the Brush-border Antigen and Mass Spectrometric 
Analysis 
 Incubation at room temperature for one hour of an excess of appropriate patient 
serum with either Protein G beads or Capture Select IgG4 (BAC BV/ThermoFisher 
Scientific/Life Technologies) preceded immunoprecipitation (IP) to concentrate the 
immunoglobulins or specifically IgG4, respectively. Then, the beads were washed with 
PBS to remove excess sera components and incubated with human kidney extract 
(glomerular or tubular) for two hours at 4°C. Following another set of washes, PBS was 
removed and the IP pellet was frozen at -20°C until it could be run on a gel for Western 
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blot as above. Once the location of the appropriate band was determined with one 
Western blot, we cut out and sent the corresponding 250-350 kDa region of another 
identical gel with the immuno-precipitates from tubular extract for mass spectrometry 
analysis of the peptides in each patient serum and normal control serum (looking for 
proteins present in the IP from the case patient, and not in the normal).  
Screen of MN Sera for Reactivity with CR1 
Reagents for human CR1 were kindly provided by John Atkinson at Washington 
University, St. Louis, MO. CR1 lysate (in a ratio of 1:4:2 with PBS and 4x loading 
buffer), glomerular TBS supernatant, and HGE were run on 4-15% Mini-PROTEAN 
TGX gels as above and incubated in primary antibody overnight. For the lanes containing 
CR1 lysate, various MN sera served as the source of primary antibody (with one 
additional case from a patient with dense deposit disease, a glomerular disease associated 
with severe complement dysregulation), and sheep-anti-human IgG4 served as the source 
of secondary antibody. Anti-CR1 rabbit polyclonal antibody (1:5000) was incubated with 
the glomerular TBS supernatant and one HGE blot. The IgG4-containing blots were 
incubated with donkey-anti-sheep IgG as usual, and the lanes blotted with the rabbit 
polyclonal antibody were next incubated in anti-rabbit -HRP, 1:5000. All blots were then 
treated with ECL solution and exposed as above.  
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RESULTS 
Biotinylation of the 58-kDa Antigen 
According to our hypothesis that relevant target antigens in primary MN should 
have epitopes exposed on the cell surface, we biotinylated cells isolated from kidneys 
prior to extraction to label cell structures that existed on the outside of cells. Western 
blotting of streptavidin bead pull-downs from a biotinylated HGE and a control non-
biotinylated HGE with α-58-kDa antigen+ serum specifically detected the antigen in the 
biotinylated reaction (Figure 5). Anti-58-kDa antigen+ serum reacted with only the 
biotinylated HGE pull-down as well (figure 5).  
 
Figure 5. Biotinylation of 58-kDa Antigen. Lane 1: HGE. Lane 2: biotinylated-HGE 
pulled down with streptavidin beads. Lane 3: Non-biotinylated-HGE incubated with 
streptavidin beads. Blotted with α-58-kDa antigen+ serum primary antibody, and sheep-
anti-human IgG1 secondary antibody. Arrow: 58-kDa antigen. The strong bands at 140 
kDa and the weak bands at 50 kDa represent non-specific binding.  
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Lectin Binding Assay 
To determine whether the 58-kDa antigen might be a glycoprotein that could 
potentially be purified by means of a lectin column, we sequentially ran HGE first 
through a wheat germ agglutinin (WGA) column and then a concanavalin A (ConA) 
column. The flow-through fractions after the first (WGA) and then both (WGA + ConA) 
types of lectin columns (i.e. what did not bind either type of column) was run on a gel 
and Western blotted as above against sera from three MN patients, each reactive with one 
of the three known autoantigens. In contrast to PLA2R and to THSD7A, both of which 
were completely removed from HGE after incubation with the immobilized WGA beads, 
the 58-kDa antigen was detected in both flow-through fractions (figure 6). The successive 
decrease in band intensity is more likely reflective of the small amount of dilution that 
occurred throughout the experiment, rather than a small amount of binding to the column. 
This result suggests that the 58-kDa antigen does not possess glycan chains capable of 
binding to the WGA or ConA lectins.  
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Figure 6. 58-kDa Antigen over WGA and ConA columns. The starting HGE fraction, 
the flow-through from the WGA column (After WGA), and the flow-through from the 
ConA column (After ConA) were immunoblotted with patient serum and detected for the 
relevant subclass (parentheses). The α-PLA2R+ and α-THSD7A+ sera were used at 
1:200; the α-58-kDa antigen+ serum was used at 1:100.  
 
Ion Exchange Assays 
 To determine whether we could utilize the charge of the 58-kDa antigen for 
further purification of the protein, we ran HGE over a variety of ion exchange columns 
and collected flow-through and eluate fractions to run on gels for Western blot with α-58-
kDa+ serum. There was early indication that the strong cation exchange column might be 
most effective. The experiment was run on strong cation exchange columns because it 
was believed that the protein was negatively charged from previous experiments 
(unpublished data). The experiments yielded inconsistent results, which might have been 
due to the age of the reagents; this line of experimentation was not pursued further.  
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Affinity Purification 
 To specifically immunoprecipitate the 58-kDa antigen for mass spectrometry 
analysis, we attempted to purify autoantibodies to the antigen via elution with acid. On 
the first attempt at affinity purifying autoantibodies to the 58-kDa antigen, it was found to 
be present with both eluates from affinity purification and milk alone. However, upon 
blotting the eluates with IgG1 only, the IgG was not reactive with the eluted fractions. 
These results were supported by repeating the experiment with mincing of the 
nitrocellulose strips to completely immerse the nitrocellulose in the acid solution and 
vigorously vortex and heat for elution. We were not able to elute the antibody from the 
nitrocellulose membrane in any of our attempts.  
Partition Phase Separation 
Tx-114 is a detergent with unique properties that allow it to separate out of the 
aqueous phase when warmed. We used phase partitioning with pre-condensed Tx-114 to 
assess if the 58-kDa antigen would associate with the detergent (Tx-114) phase or with 
the aqueous phase, to determine the relative hydrophobicity vs. hydrophilicity of the 
antigen. The aqueous phases, after phase partitioning extracts from whole human 
glomeruli or from a TBS glomerular supernatant starting preparation, were Western 
blotted with α-PLA2R+ and α-58-kDa antigen+ sera. Anti-PLA2R+ serum reacted with 
the aqueous phase (figure 7A). Anti-58-kDa antigen+ serum did as well, but the reaction 
was stronger against the glomerular aqueous layer than it was against the glomerular TBS 
supernatant aqueous layer (figure 7B). For α-58-kDa antigen+ serum, the reaction was 
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stronger in the aqueous layer that was partitioned after using the aqueous phase of the 
first step with fresh pre-condensed Tx-114 (figure 7B).  
 
Figure 7. Partition Phase Separation of PLA2R and 58-kDa Antigen. Lane 1: 
Glomerular TBS Supernatant, Lane 2: Glomerular TBS Supernatant Aqueous Layer 1, 
Lane 3: Glomerular TBS Supernatant Aqueous Layer 2, Lane 4: Glomeruli Aqueous 
Layer 1, Lane 5: Glomeruli Aqueous Layer 2, Lane 6: HGE.   
 
Proteolysis of Brush-border Antigen via Trypsin, Sensitivity to Reducing 
Conditions, and Content of HGE 
During our experiments designed to characterize the 58-kDa antigen, we began 
collaboration on a project that employed similar methods in an attempt to identify another 
kidney antigen targeted in an autoimmune process. Namely, our collaborators had 
identified a small cohort of cases associated with glomerular subepithelial and tubular 
basement deposits in the setting of autoimmune tubulointerstitial nephritis. Of note, all 
these sera contained IgG that localized to normal proximal tubular brush border, 
suggestive of autoantibodies to a putative brush border protein. We set out to determine if 
these patient sera could identify a common target antigen.  Anti-brush-border antigen+ 
sera from four different patients were shown to interact with what appeared to be a 
similar antigen in an HGE preparation that was known to contain tubular elements 
(figures 8 and 9). However, that antigen was not detected by control or α-PLA2R+ sera.   
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Figure 8. Common brush border antigen amongst ABBA sera but not negative 
controls. Lanes 1-4: HGTE blotted with four different α-brush-border antigen+ patient 
sera. Lanes 5-9: Negative controls. Lane 1 incubated with sheep-anti-human IgG1 
secondary antibody; others incubated with sheep-anti-human IgG4.  
 
 
Figure 9. Photomicrograph of human glomerular extract with tubular elements 
(100x). Glomeruli are indicated with black arrows. Tubules are indicated with black 
arrow heads. Blue arrow heads indicate cell ghosts. From Laurence Beck, unpublished 
data. 
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In addition, experiments were run to determine the sensitivity of the brush border 
antigen to reducing conditions, as well as the reactivity of the antibodies with standard 
HGE (without contaminating tubular elements). Running HGE with tubular elements 
(HGTE) on a gel under reducing and non-reducing conditions and blotting against anti-
brush-border antibody (ABBA)-4 serum yields a band only under non-reducing 
conditions (figure 10). Furthermore, there is not a visible band present on Western blot of 
HGE without tubular elements against ABBA-4 serum (data not shown), suggesting that 
the candidate antigen we have characterized is indeed from tubular cells. 
 
Figure 10. Brush border antigen reducing vs. non-reducing conditions. Lane 1: 
HGTE, non-reducing conditions. Lane 2: HGTE, reducing conditions. Blotted with α-
brush-border antigen+ patient serum, 1:100, primary antibody and sheep-anti-human 
IgG4 secondary antibody. 
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To narrow down the immunoreactive element that reacted with α-brush-border 
antigen+ sera, HGTE was treated with increasing amounts of trypsin ranging from 0-25% 
(Note: the starting (“100%”) trypsin was a cell culture preparation containing only 0.05% 
trypsin) and incubated at 37°C for 15 minutes before heat denaturation prior to Western 
blotting. When immunoblotted with ABBA-4 serum, reactive bands are observed at about 
140 kDa, 120 kDa, and 95 kDa (figure 11). The band at 95 kDa appears to be stable as it 
is present in all the trypsinized conditions. There are no visible bands smaller than the 95 
kDa band with patient serum.  
 
 
Figure 11. Partial proteolysis of brush border antigen with trypsin. HGTE 
proteolyzed with increasing amounts of trypsin was immunoblotted with α-brush-border 
antigen+ patient serum (1:100) and detected for IgG4.  
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Biotinylation and Immunoprecipitation of Brush Border Antigen 
 Separate extracts of tubular cells, with and without biotinylation, were prepared as 
described in the Methods. Western blotting with streptavidin-HRP confirmed robust 
biotinylation of the human tubular extract (HTE). Biotinylated- and non-biotinylated-
HTE were then separately immunoprecipitated with ABBA-4 serum using reagents to 
pull down either total IgG (protein G beads) or the IgG4 subclass alone (Capture Select 
anti-human IgG4 beads). The IP pellet was electrophoresed under non-reducing and 
reducing conditions and Western blotted with streptavidin-HRP. The antigenic band of 
interest appeared to be destroyed under reducing conditions when pulled down with total 
IgG, and became more concentrated when pulled down specifically by IgG4 (figure 
12A). Biotinylated-HTE was also immunoprecipitated with purified α-PLA2R+ and 
normal human IgG4 as controls, and α-megalin+ IgG. Western blot with streptavidin-
HRP determined that a single biotinylated band was specifically pulled down by the 
ABBA-4 serum, but not the α-PLA2R+ serum, the normal human serum, or the α-
megalin+ antibody (figure 12B).  
IPs of biotinylated and non-biotinylated HTE with ABBA-4 IgG4 as well as an IP 
of non-biotinylated HTE with control IgG4 were run on identical gels as in the Methods. 
Then, the band corresponding to the brush-border antigen was localized with streptavidin 
on one gel and the gel regions corresponding to the exact position of the band (from all 
three lanes shown in figure 12C) were excised from the other gel. Upon sending the gel 
regions to our collaborators at the University of Louisville for mass spectrometry 
analysis, several proteins were considered as candidates for the brush-border antigen 
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based on the ratio of the amount of peptides identified in the patient IP to the control IP 
(table 2). Low-density lipoprotein receptor-related protein 2 (megalin) and sushi, von 
Willebrand factor type A, EGF and pentraxin domain-containing protein 1 (SVEP1) were 
the strongest candidates based on size and tissue expression. Glycosylation and cellular 
location were also considered.  
A.  B.  
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C.  
Figure 12. Brush border antigen IP. Western blot with Streptavidin-HRP, 1:2500. A. 
Initial IP of HTE (either biotinylated and non-biotinylated) immune-precipitated with α-
brush-border antigen+ IgG, or specifically, IgG4. Each IP was run in duplicate, under 
reducing and non-reducing conditions. B. IP of biotinylated HTE & controls. Lane 1: IP 
with α-brush-border antigen+ serum purified by Capture Select IgG4; (relevant band 
indicated with arrow) Lane 2: IP with α-PLA2R+ serum purified by Capture Select IgG4; 
Lane 3: IP with normal human serum purified by Capture Select IgG4; Lane 4: IP with α-
megalin+ antibody purified by Protein G. C. Identical gel of preparative IP of HTE for 
mass spectrometry with sera purified by Capture Select IgG4 that was blotted and 
detected with streptavidin; excised bands were from the corresponding lanes of a gel that 
was not transferred.  
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Table 2. List of best candidate proteins for brush-border antigen from mass 
spectrometry analyses (Data from “Human Protein Reference Database,” n.d.) 
Protein Size Ratio 
ABBA+/ 
Control 
Glycosylation Tissue 
Expression 
Cellular 
Location 
Alpha-1-
antitrypsin 
47 ABBA+ 
only 
No White blood 
cells, liver, 
mammary 
gland, ovary, 
placenta 
Extracellular, 
ER, 
lysosome, 
cytoplasm 
Cluster of Ig 
heavy chain 
V-III region 
BRO 
13 13.46 No Plasma, 
saliva, urine 
Extracellular, 
plasma 
membrane 
Isoform 14 of 
Fibronectin 
249 109.56 N Liver, white 
blood cells, 
plasma, 
serum, skin, 
urine 
Extracellular, 
ER 
Isoform 2 of 
Fibrinogen 
alpha chain 
70 ABBA+ 
only 
N Blood, liver, 
plasma, urine 
Extracellular 
Isoform C of 
Proteoglycan 
4 
141 ABBA+ 
only 
No Bone, heart, 
liver, lung, 
serum, urine 
Extracellular 
Low-density 
lipoprotein 
receptor-
related protein 
2 (Megalin) 
522 277.36 No Brain, fetus, 
kidney, lung, 
parathyroid, 
placenta, 
proximal 
convoluted 
tubule, urine 
Plasma 
membrane, 
endosome 
Protein 
IGHV3-30 
(fragment) 
13 ABBA+ 
only 
No Plasma, 
saliva, urine 
Extracellular, 
plasma 
membrane 
Sushi, von 
Willebrand 
factor type A, 
EGF and 
pentraxin 
domain-
containing 
protein 1 
390 ABBA+ 
only 
N and O Placenta, 
marrow 
Cytoplasm, 
membrane, 
extracellular 
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Screen of MN Sera for Reactivity with CR1 
 Finally, we took a candidate antigen approach to screen for other potential 
autoantibodies in MN. Because antibodies to Crry (similar to human CR1) were found in 
the sheep anti-Fx1a preparation and were necessary for causing disease in the Heymann 
nephritis model, we hypothesized that CR1 might be a relevant target antigen in human 
primary MN that might exacerbate complement-mediated injury. We assayed serum from 
patients with PLA2R-associated and non-PLA2R-associated MN for reactivity with 
recombinant CR1. Upon Western blotting α-PLA2R+ sera against CR1 lysate, none of the 
serum reacted with the lysate (figure 13). In addition, α-CR1+ antibody did react with 
glomerular TBS supernatant fraction and HGE (figure 13). 
 
Figure 13. CR1 reactivity screen. Lane 1: glomerular supernatant fraction. Lane 2: 
HGE. Lanes 3-11: recombinant CR1 cell lysate. Lanes 1 & 2 blotted with α-CR1+ 
antibody; lanes 3-10 blotted with MN sera; lane 11 blotted with serum from a patient 
with dense deposit disease.   
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DISCUSSION 
Using lines of experimentation similar to those used to identify PLA2R and 
THSD7A as the first two target antigens in adult primary MN, we have been able to 
better characterize other kidney-derived antigenic targets of human autoantibodies and 
have made significant headway into identifying one of them. It was determined that one 
antigen of interest, a 58-kDa antigen that is recognized by sera from several patients with 
MN, was biotinylated, implying that the antigen is likely to be extracellular. Our work on 
the 58-kDa antigen suggests that it is extracellular, not heavily glycosylated, and not a 
transmembrane protein. We made a novel discovery that cases of autoimmune 
tubulointerstitial nephritis with tubular basement membrane deposits all seem to have 
autoantibodies to a common antigen. We have made significant progress in identifying 
the actual antigen, with only a small number of likely candidate proteins, including 
megalin and SVEP1.  
Antigens found on the outside of cells, such as PLA2R and THSD7A, are of 
interest because they would be interacting with antibodies, so we first chose to confirm 
the extracellular location of these putative autoantigens via biotinylation. Biotinylation of 
extracellular structures was successful as shown by the reactive binding of streptavidin-
HRP to biotinylated HGE only, as opposed to HGE that was not biotinylated and thus not 
reactive with streptavidin-HRP. It was determined that the antigen of interest (58-kDa) 
was indeed biotinylated by the reaction of the α-58-kDa+ patient serum with the 
biotinylated HGE only. From the successful biotinylation of the 58-kDa antigen, we 
concluded that this antigen in fact contained portions on the outside of cells, and was 
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therefore potentially interesting as an extracellular epitope capable of being targeted by 
autoantibodies.  
Wheat germ agglutinin and concanavalin A are lectins that bind membrane 
proteins that are N-glycosylated (Pohleven et al, 2012). The lack of binding of the 58-
kDa antigen to either type of lectin binding column tested suggests that it is not highly 
glycosylated. The validity of this experiment comes from the fact that neither PLA2R nor 
THSD7A (both of which are known N-glycosylated glycoproteins) were present in the 
flow through as detected by Western blot with the appropriate human serum. This 
experiment allowed for further characterization of the 58-kDa antigen, as we now know 
that it is not likely to be N-glycosylated, and offers a method for partial purification of 
the antigen by separating it from the bulk of glomerular glycoproteins.  
Our inconsistent results with ion exchange columns did not add to the 
characterization of the 58-kDa antigen or offer a potential avenue for further partial 
purification. These contradictory results could be due to the columns used being past their 
expiration date or an inappropriate equilibration buffer being used. After attempting to 
affinity purify the α-58-kDa antigen+ autoantibody, which would have been able to 
specifically IP the antigen for mass spectrometry purposes, it was suspected that the 
antigen-bound antibody was not eluted off the nitrocellulose membrane from the 
reactivity of both α-58-kDa antigen and milk only with the eluted fractions. This was 
confirmed by the lack of reactivity in the presence of IgG1 only. Additionally, because 
immunoblotting is a very sensitive technique and may overestimate the mass of antigen 
and/or autoantibody present, the actual amounts of eluted, affinity purified autoantibody 
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may have been miniscule and therefore undetectable using the small-scale preparation 
that we used. 
Our TX-114 phase separation experiments were intended to distinguish 
hydrophobic transmembrane proteins that would partition in the detergent phase, from 
hydrophilic soluble proteins that would partition into the aqueous phase. The mild, non-
ionic Tx-114 detergent gently solubilizes membrane proteins and separates them from 
hydrophilic proteins via phase partitioning above 20°C (the detergent is homogeneous at 
0°C; Qoronfleh, Benton, Ignacio, & Kaboord, 2003). This results in an aqueous layer of 
hydrophilic (peripheral and cytosolic) proteins and a detergent layer of integral 
membrane proteins. The fact that α-PLA2R+ serum reacted with the aqueous layer 
obtained by partition phase separation indicates that the protocol for this experiment may 
need to be enhanced with additional partitioning steps. It is known that PLA2R is a 
transmembrane protein, and thus α-PLA2R+ serum should not have reacted with the 
aqueous layer. However, the fact that α-58-kDa+ serum reacted more strongly against the 
second phase partitioned aqueous phase than it did with the first may indicate that the 
phase partition separation was concentrating the 58-kDa antigen into the aqueous layer 
and that it is not a trans-membranous protein. This is consistent with previous work in the 
laboratory (unpublished data) suggesting that the 58-kDa antigen was a membrane-
associated protein that could be solubilized using pH 9.5 sodium carbonate buffer. The 
fact that the antigen signal is stronger in the glomerular sample than in the glomerular 
TBS supernatant sample via Western blot may simply be due to the antigen being more 
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concentrated in the glomeruli itself and not shed in the membrane particles thought to 
comprise the TBS glomerular supernatant fraction.  
The next steps in the identification of the 58-kDa antigen may include an initial 
partial purification with lectin columns, followed by phase partitioning (since that was 
shown to contain the 58-kDa antigen and it is purer than the original HGE product), and 
then immunoprecipitation. We could also try adding an extra partitioning step to this 
purification experiment for added purity. Then we could remove any contaminating IgG 
with Protein G beads and have a suitable product to send for analysis via mass 
spectrometry.  
During my experiments designed to characterize the 58-kDa antigen, we were 
fortunate enough to collaborate on a project that employed similar methods in an attempt 
to identify another kidney antigen targeted in an autoimmune process. A case report 
describing autoantibodies to a brush border antigen demonstrated that these antibodies 
were associated with tubular immune deposits as well as minor subepithelial glomerular 
deposits (Rosales et al., 2015). We decided to pursue the identification of this new 
candidate antigen based on techniques that had been successful in the identification of 
PLA2R and THSD7A were identified. Our first significant finding was that there is a 
common antigen (according to banding on Western blot) that is recognized by 100% of 
the ABBA sera. This antigen is even more prominent among ABBA sera than PLA2R is 
among MN sera, with only 75-80% of cases having reactivity.  
The proteolysis of the brush border antigen with trypsin yielded an apparently 
stable band at about 95 kDa that was theorized to contain the immunoreactive epitope to 
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be immunoprecipitated for mass spectrometry. The lack of reactive bands on Western 
blot under reducing conditions and with HGE indicates that the brush border antigen is 
sensitive to reducing conditions as well as present in tubules. The sensitivity of the 
antigen under reducing conditions could be explained by the biotin chains becoming less 
available to streptavidin when the polypeptide chain is linearized by boiling and 
reduction. Or perhaps reduction makes the antigen more “sticky” and it gets entangled in 
the beads, and does not make it onto the gel. The single biotinylated band specifically 
pulled down by the α-brush-border antigen+ serum, but not the α-PLA2R+ serum nor the 
normal human serum, was determined to be useful for preparative IP and subsequent 
mass spectrometry analysis.  
Mass spectrometry analysis of HTE immune-precipitated with ABBA-4 serum 
provided a list of potential candidates for the brush-border antigen. Out of the proteins 
with peptides that were only found in the immune-precipitates from the patient, and not 
in the control, SVEP1 was the only one with a molecular mass close to that of the band 
we observed on Western blot. However, SVEP1 is not detected in kidney brush border; 
but rather, it is a ligand for an integrin (Sato-Nishiuchi et al., 2012). It is also unlikely 
that the antigen is an isoform of fibronectin, because that is not expressed in kidney 
tissue. So, that leaves the other antigen within a reasonable size range: megalin. Megalin 
was predominantly found in the immune-precipitates from the patient rather than in that 
from the control. While megalin is in fact larger than the protein band we identified, it 
was originally thought to be a 330 kDa protein, but is in fact closer to 600 kDa (Saito, 
Pietromonaco, Loo, & Farquhar, 1994). Although megalin was initially ruled out as the 
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brush-border antigen by immunofluorescence, there could be a distinct form or portion of 
megalin recognized by patient serum but not commercial antibody, as is the case with 
THSD7A. Patient serum also failed to detect an antigenic band immune-precipitated with 
the commercial antibody, but it has not actually been confirmed that the antibody works 
for IP, similar to how it does not work in Western blot. Therefore, while megalin is the 
strongest candidate for the brush-border antigen at this point, this and other potential 
candidates will need to be tested further.  
With the mass spectrometry results analyzed, we can proceed with the next steps 
in identifying the brush border antigen. These next steps may include Western blotting 
with commercial antibodies of proteins determined to be present by mass spectrometry or 
transfecting cells with cDNA clones of the protein sequence and extracting proteins from 
the cells grown up expressing the antigen. In the meantime, we may also want to run 
HTE over WGA or ConA columns and blot with α-brush-border antigen+ patient serum 
to determine whether the brush border antigen is a glycoprotein that may be bound by a 
lectin column. We could also do more IPs with serum from other patients with this 
disease to get material for mass spectrometry. Looking forward, the positive staining of 
rat glomeruli with human α-brush-border antigen+ serum is promising for potential use of 
an animal model of membranous nephropathy elicited by autoimmunity to brush border 
antigens.  
Since anti-Crry antibodies were present in the anti-Fx1A preparation necessary to 
cause Heymann nephritis in the rat model, we decided to screen a group of MN sera to 
determine whether or not they contained antibodies to CR1. In fact, none of the sera 
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reacted to the CR1 lysate run on a gel for Western blot. In addition, anti-CR1+ antibody 
reacted with HGE and the glomerular TBS supernatant fraction. However, autoantibodies 
to CR1 in podocytes does not appear to be the case in the human primary MN cases we 
tested.  
 Here we have applied a technique that has been shown to be instrumental in 
discovering new autoantibody-autoantigen systems in renal disease. This technique 
involves screening serum samples via Western blotting; purifying potential MN antigens; 
identifying them with mass spectrometry; and validating their identity with 
immunoprecipitation and immunohistochemical analysis. This process affords the 
possibility of new biomarkers, insight into pathomechanisms of human diseases, and 
therapy that targets antigens responsible for disease.   
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